Modifications of C-2 on the pyrroloquinoline template aimed at the development of potent herpesvirus antivirals with improved aqueous solubility

  • Bioorg Med Chem Lett. 2010 May 15;20(10):3039-42. doi: 10.1016/j.bmcl.2010.03.115.
James A Nieman  1 ,  Sajiv K Nair ,  Steven E Heasley ,  Brenda L Schultz ,  Herbert M Zerth ,  Richard A Nugent ,  Ke Chen ,  Kevin J Stephanski ,  Todd A Hopkins ,  Mary L Knechtel ,  Nancee L Oien ,  Janet L Wieber ,  Michael W Wathen
Affiliations
  • 1. Global Research and Development, Pfizer, Inc., Kalamazoo, MI 49007, USA. [email protected]
PMID: 20403696 DOI: 10.1016/j.bmcl.2010.03.115
Abstract

A series of C-2 pyrroloquinoline analogs designed to improve aqueous solubility were examined for herpesvirus polymerase and Antiviral activity. Several analogs were identified that maintained the Antiviral activity of the previous development candidate against HCMV, HSV-1 and VZV, but with significantly improved aqueous solubility.